Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy |Feb 02, 2012
Expression levels of CGEN-15001T on various solid, hematological cancer cells and immune cells combined with its immunomodulatory activities support its potential use as a powerful drug target for cancer immunotherapy
Compugen Presents Three Product Candidates for Treatment of Autoimmune Diseases at the Immunotherapeutics & Immunomonitoring Conference|Jan 30, 2012
Presentation demonstrates the therapeutic effects of CGEN-15001, CGEN-15021 and CGEN-15091 in disease animal models of rheumatoid arthritis and multiple sclerosis
Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology|Dec 20, 2011